Matt Truman

1.1k total citations · 1 hit paper
25 papers, 632 citations indexed

About

Matt Truman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Matt Truman has authored 25 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Rheumatology. Recurrent topics in Matt Truman's work include Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Matt Truman is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Matt Truman collaborates with scholars based in Australia, Switzerland and United States. Matt Truman's co-authors include Tony Mok, Yi‐Long Wu, Chong‐Jen Yu, Sumitra Thongprasert, Vichien Srimuninnimit, Virote Sriuranpong, Guia Ladrera, Barbara Klughammer, Jennifer Sandoval-Tan and David S. Shames and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Matt Truman

24 papers receiving 625 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

2015 367 citations Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matt Truman Australia	12	393	337	269	101	80	25	632
Christopher Lanigan United States	12	218 0.6×	111 0.3×	322 1.2×	102 1.0×	104 1.3×	27	541
Haruko Daga Japan	16	611 1.6×	182 0.5×	594 2.2×	181 1.8×	55 0.7×	92	911
D J Park South Korea	5	105 0.3×	77 0.2×	338 1.3×	319 3.2×	172 2.1×	6	652
Srinivas K. Tantravahi United States	11	242 0.6×	125 0.4×	173 0.6×	245 2.4×	52 0.7×	70	597
A.H. Honkoop Netherlands	10	107 0.3×	211 0.6×	298 1.1×	135 1.3×	78 1.0×	20	577
Milena Perez Mak Brazil	12	234 0.6×	137 0.4×	399 1.5×	189 1.9×	43 0.5×	34	664
Ilya Tsimafeyeu Russia	15	360 0.9×	143 0.4×	216 0.8×	325 3.2×	22 0.3×	111	628
Jae Young Joung South Korea	16	589 1.5×	186 0.6×	355 1.3×	237 2.3×	23 0.3×	83	929
N. J. Vogelzang United States	16	290 0.7×	89 0.3×	302 1.1×	286 2.8×	48 0.6×	38	759
A. Plantade France	8	381 1.0×	220 0.7×	144 0.5×	323 3.2×	34 0.4×	17	590

Countries citing papers authored by Matt Truman

Since Specialization

Citations

This map shows the geographic impact of Matt Truman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Truman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Truman more than expected).

Fields of papers citing papers by Matt Truman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Truman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Truman. The network helps show where Matt Truman may publish in the future.

Co-authorship network of co-authors of Matt Truman

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Truman. A scholar is included among the top collaborators of Matt Truman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Truman. Matt Truman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Truman, Matt, Christopher Dodoo, Charles H. Adler, et al.. (2025). Improving radiology reporting accuracy: use of GPT-4 to reduce errors in reports. Abdominal Radiology. 51(1). 513–520.

Dall’Era, Maria, Kenneth Kalunian, Neil Solomons, et al.. (2024). Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Science & Medicine. 11(2). e001319–e001319. 1 indexed citations

McDonald, Stephen, Li Su, Caroline Gordon, et al.. (2022). Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Science & Medicine. 9(1). e000584–e000584. 8 indexed citations

Menn‐Josephy, Hanni, Matt Truman, Mary Palmen, & Paola Mina‐Osorio. (2021). Voclosporin Is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis. Journal of the American Society of Nephrology. 32(10S). 48–48. 1 indexed citations

Youssef, Peter, Peter Button, Matt Truman, et al.. (2019). Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. The Journal of Rheumatology. 47(8). 1174–1181. 11 indexed citations

Woodward, Natasha, Richard H. De Boer, Andrew Redfern, et al.. (2019). Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). Clinical Breast Cancer. 19(3). 216–224. 11 indexed citations

Dall’Era, Maria, N. Solomons, Rodolfo Federico, & Matt Truman. (2019). Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus. 28(5). 591–596. 19 indexed citations

Woodward, Natasha, et al.. (2017). Abstract P4-21-31: Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Cancer Research. 77(4_Supplement). P4–21. 4 indexed citations

Pivot, Xavier, C. J. Poole, Miguel Martín, et al.. (2016). An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies. Annals of Oncology. 27. vi63–vi63. 1 indexed citations

10.

Mok, Tony, Guia Ladrera, Vichien Srimuninnimit, et al.. (2016). Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. 98. 1–8. 22 indexed citations

11.

Woodward, Natasha, et al.. (2016). Abstract P4-14-12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Cancer Research. 76(4_Supplement). P4–14. 2 indexed citations

12.

Locatelli, Francesco, et al.. (2016). Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Advances in Therapy. 33(4). 610–625. 6 indexed citations

13.

Panizo, Carlos, Mohamed Amine Bekadja, Balkis Meddeb, et al.. (2016). Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study. Blood. 128(22). 2971–2971. 3 indexed citations

14.

Mok, Tony, Yi‐Long Wu, Jin Soo Lee, et al.. (2015). Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research. 21(14). 3196–3203. 367 indexed citations breakdown →

15.

Dall’Era, Maria, Victoria Levesque, Neil Solomons, Matt Truman, & David Wofsy. (2015). Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science & Medicine. 2(1). e000089–e000089. 39 indexed citations

16.

Tran, Huyen, Tim Brighton, Andrew Grigg, et al.. (2014). A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study). British Journal of Haematology. 167(2). 243–251. 24 indexed citations

17.

Mok, Tony, L. Zhang, Chong‐Jen Yu, et al.. (2012). Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix400–ix401. 13 indexed citations

18.

Mok, Tony, Yi‐Long Wu, Sumitra Thongprasert, et al.. (2012). A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.. Journal of Clinical Oncology. 30(15_suppl). 7519–7519. 21 indexed citations

19.

Nashan, Björn, Faouzi Saliba, François Durand, et al.. (2009). Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transplantation. 15(2). 136–147. 32 indexed citations

20.

Boyd, Mark, et al.. (2008). A Randomized Study to Evaluate Injection Site Reactions using Three Different Enfuvirtide Delivery Mechanisms (the OPTIONS Study). Antiviral Therapy. 13(3). 449–454. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact